Development of HIF-1 inhibitors for cancer therapy.
Intratumour hypoxia has long been considered a driving force of tumour progression and a negative prognostic factor in human cancers. The discovery of hypoxia inducible factors (HIFs), which mediate transcriptional responses to changes in oxygen levels, has renewed enthusiasm for the discovery and development of targeted therapies exploiting the hypoxic tumour microenvironment. In spite of an ever increasing number of putative small molecule inhibitors of HIF, only few progress through pre-clinical and early clinical development. In this review, we will focus primarily on: (1) HIF inhibitors that have been more recently described and (2) small molecules targeting HIF that are being tested in early clinical trials or that are already approved for use in patients. A rigorous 'validation' of HIF targeted therapies in relevant pre-clinical models and eventually in pharmacodynamic-based early clinical trials is essential for 'credentialing' HIF-1 as a legitimate target that can be pharmacologically modulated in cancer patients.
Onnis
Barbara
B
Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, Frederick, MD 21702-1201, USA.
Rapisarda
Annamaria
A
Melillo
Giovanni
G
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D055808:Drug Discovery; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D051793:Hypoxia-Inducible Factor 1
J Biol Chem. 1997 Sep 5;272(36):22642-7
9278421
Nat Rev Drug Discov. 2003 Oct;2(10):803-11
14526383
J Nat Prod. 2009 May 22;72(5):805-12
19405508
Biochem Biophys Res Commun. 1995 Nov 13;216(2):669-75
7488163
Drug Discov Today. 2007 Oct;12(19-20):853-9
17933687
Clin Cancer Res. 2007 Feb 1;13(3):1010-8
17289897
Mol Cell Biol. 2009 Apr;29(8):2243-53
19223463
Anticancer Res. 2003 Mar-Apr;23(2C):1673-80
12820439
Blood. 2002 Nov 15;100(10):3767-75
12393646
Genes Dev. 2000 Feb 15;14(4):391-6
10691731
J Biol Chem. 2008 Jun 13;283(24):16309-19
18430730
Cancer Control. 2003 Sep-Oct;10(5):361-9
14581890
Cancer. 2009 Aug 15;115(16):3618-30
19479976
Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2353-8
19168635
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
7539918
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):680s-684s
17255293
Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19579-86
19020076
Mol Cancer Ther. 2008 Jan;7(1):90-100
18202012
Methods Enzymol. 2007;435:385-402
17998065
Cancer Lett. 2009 Aug 8;280(2):145-53
19111391
Mol Cancer Ther. 2003 Mar;2(3):235-43
12657718
Mol Cell Biol. 2006 Aug;26(15):5895-907
16847340
Mol Cell Biol. 2001 Jun;21(12):3995-4004
11359907
Cancer Res. 2004 Feb 15;64(4):1475-82
14983893
Clin Cancer Res. 2005 Aug 1;11(15):5526-33
16061869
Nat Med. 2004 Jun;10(6):594-601
15156201
J Biosci. 2007 Apr;32(3):517-30
17536171
Cancer Invest. 2004;22(2):304-11
15199612
Blood. 2008 Mar 15;111(6):3131-6
18174379
J Natl Cancer Inst. 2005 Sep 7;97(17):1272-86
16145048
Mol Cancer Ther. 2009 Jul;8(7):1867-77
19584228
Neuro Oncol. 2005 Jul;7(3):225-35
16053697
Mol Pharmacol. 2002 Nov;62(5):975-82
12391259
Cancer Cell. 2004 Jul;6(1):33-43
15261140
Nat Rev Cancer. 2004 Jun;4(6):437-47
15170446
Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16768-73
15556999
Mol Cancer Ther. 2008 Nov;7(11):3598-608
18974394
Clin Cancer Res. 2008 Mar 15;14(6):1888-96
18347192
J Biol Chem. 2002 Aug 16;277(33):29936-44
12052835
Cancer Res. 2004 Oct 1;64(19):6845-8
15466170
Oncogene. 2005 Jun 23;24(27):4433-41
15806152
Curr Top Med Chem. 2006;6(11):1163-71
16842153
Lancet. 2008 Aug 9;372(9637):449-56
18653228
Nat Rev Cancer. 2008 Nov;8(11):851-64
18846101
Cancer Metastasis Rev. 2007 Jun;26(2):341-52
17415529
Cancer Res. 2006 Jun 1;66(11):5549-54
16740688
Mol Cancer Ther. 2004 Mar;3(3):233-44
15026543
Neoplasia. 2006 May;8(5):394-401
16790088
Cancer Cell. 2003 Apr;3(4):363-75
12726862
Science. 2009 Jun 5;324(5932):1289-93
19498162
Nat Med. 2006 Jan;12(1):122-7
16341243
Cancer Res. 2005 Oct 1;65(19):9047-55
16204079
J Clin Oncol. 2002 Jan 1;20(1):289-96
11773181
Biochem Biophys Res Commun. 2003 Feb 28;302(1):95-100
12593853
Cancer Res. 2002 Aug 1;62(15):4316-24
12154035